Comment on

• Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.

  Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, Douglass LR, Lazzeroni LC, Holodniy M, Owens DK. Sanders GD, et al. N Engl J Med. 2005 Feb 10;352(6):570-85. doi: 10.1056/NEJMsa042657. N Engl J Med. 2005. PMID: 15703422
• Expanded screening for HIV in the United States--an analysis of cost-effectiveness.

  Paltiel AD, Weinstein MC, Kimmel AD, Seage GR 3rd, Losina E, Zhang H, Freedberg KA, Walensky RP. Paltiel AD, et al. N Engl J Med. 2005 Feb 10;352(6):586-95. doi: 10.1056/NEJMsa042088. N Engl J Med. 2005. PMID: 15703423